Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ixempra

- PMLiVE

Lilly enters cancer collaboration in China

Signs deal with Chi-Med to develop and commercialise fruquintinib

Bayer symbol

Bayer expects five drugs to enter phase III in 2015

Hopes to follow success of recent launches

- PMLiVE

Rise of generic medicines in Portugal

From a nation in love with branded medicines to one reliant on generics

- PMLiVE

Indian pharma market set for ‘significant’ growth

Forecast to be worth $56bn by 2020, despite regulatory uncertainty

- PMLiVE

NICE backs Roche’s MabThera in rare autoimmune disease

Overturns previous negative draft guidance from England's cost-effectiveness body

- PMLiVE

FDA gives green light to Roche for early Perjeta in breast cancer

Oncology drug can now be used before surgery in the US

- PMLiVE

UK breast cancer campaign tackles confidence failings

Breast Cancer Care aims to address negative impact on how women feel about their bodies

- PMLiVE

AZ moves closer to EU approval for ovarian cancer drug

Olaparib on course to be first PARP inhibitor available for ovarian cancer

- PMLiVE

ECC 2013: Nintedanib data boosts Boehringer’s oncology ambitions

Lung cancer drug shows extended overall survival in adenocarcinoma patients

National Institute for Health and Care Excellence NICE logo

NICE to update ovarian cancer drug guidelines

Draft guidance backs paclitaxel and Janssen’s Caelyx but not gemcitabine, topetecan or trabectedin

- PMLiVE

Mixed news for Lilly on cancer hope ramucirumab

Fails in phase III for breast cancer but better results for stomach cancer

- PMLiVE

Boehringer’s oncology unit scores first EU approval

Giotrif given green light for non-small cell lung cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links